Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Test Dose Phase	STARTED	USL261 TDP	292
Test Dose Phase	STARTED	USL261 CP	0
Test Dose Phase	STARTED	Placebo CP	0
Test Dose Phase	COMPLETED	USL261 TDP	201
Test Dose Phase	COMPLETED	USL261 CP	0
Test Dose Phase	COMPLETED	Placebo CP	0
Test Dose Phase	NOT COMPLETED	USL261 TDP	91
Test Dose Phase	NOT COMPLETED	USL261 CP	0
Test Dose Phase	NOT COMPLETED	Placebo CP	0
Comparative Phase	STARTED	USL261 TDP	0
Comparative Phase	STARTED	USL261 CP	134
Comparative Phase	STARTED	Placebo CP	67
Comparative Phase	COMPLETED	USL261 TDP	0
Comparative Phase	COMPLETED	USL261 CP	133
Comparative Phase	COMPLETED	Placebo CP	67
Comparative Phase	NOT COMPLETED	USL261 TDP	0
Comparative Phase	NOT COMPLETED	USL261 CP	1
Comparative Phase	NOT COMPLETED	Placebo CP	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01390220/flow